Diabetic neuropathy, a common complication of diabetes, affects approximately 50% of diabetic patients and can lead to a range of symptoms, including chronic pain, numbness, and loss of sensation in the extremities, particularly the feet. Animal models are crucial for understanding the mechanisms of diabetic neuropathy and developing novel treatments. However, reproducing the complexity of …Read More >

Diabetic retinopathy is a major contributor to vision loss and blindness in working-age adults with diabetes. Developing animal models that accurately represent human diabetic retinopathy is challenging because this disease is complex and involves multiple factors, including genetic predisposition, duration of diabetes, and glycemic control. It is crucial to replicate the human pathophysiology in these …Read More >

Poly (ADP-ribose) polymerase inhibitors (PARPi) have emerged as a promising therapeutic approach in the treatment of various cancers, particularly those with deficiencies in DNA repair mechanisms. However, the clinical efficacy of PARPi is often limited by the development of resistance, which poses a significant challenge to their long-term use. Elucidating the molecular mechanisms underlying PARPi …Read More >

Advances in understanding how the body regulates metabolism, particularly the role of incretin hormones, have directly led to the development of effective therapies for improving glycemic control and managing weight, particularly for individuals with type 2 diabetes and/or obesity. These medications, such as GLP-1 receptor agonists and dual GLP-1/GIP receptor agonists, mimic or enhance the …Read More >

The global obesity epidemic is a significant public health concern, increasing the risk of various chronic diseases, including diabetes, cardiovascular diseases, and certain cancers, ultimately reducing overall quality of life. Approximately 1-5% of severely obese patients have been found to carry heterozygous mutations in the melanocortin-4 receptor (MC4R) gene. Targeting MC4R, which regulates appetite and …Read More >

Obesity is a significant risk factor for developing conditions like type 2 diabetes, heart disease, stroke, and several types of cancer.  The cannabinoid-1 (CB1) receptor plays a significant role in regulating energy homeostasis, including appetite, food intake, and metabolism, and this receptor is emerging as a promising target for the treatment of obesity.  Although rimonabant, …Read More >

Hit validation is a crucial step in drug discovery based on DNA-encoded libraries (DEL). Rapid and accurate resynthesis of compounds, along with subsequent validation, can significantly accelerate the drug discovery process. The groups of Professors Jörg Scheuermann and Renato Zenobi from ETH Zurich developed a new method for validating on-DNA compounds with the support of …Read More >

The ATP-adenosine pathway plays a crucial role in regulating immune responses, including those involved in combating tumors. CD39 is an enzyme that breaks down ATP into adenosine. Adenosine, in turn, can suppress the immune system, potentially hindering the body’s ability to fight cancer. By inhibiting CD39, researchers aim to increase ATP levels in the tumor …Read More >

Choose excellence, choose WuXi Biology – your reliable partner in Targeted Protein Degradation (TPD) drug discovery. Since 2016, we have developed comprehensive discovery platforms capable of investigating the complete TPD functional cycle, from binary and ternary complex formation to protein ubiquitination and degradation. Our broad and deep expertise spans diverse TPD modalities, including PROTACs®, molecular …Read More >